Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Am J Surg ; 232: 131-137, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38365550

ABSTRACT

BACKGROUND: Studies comparing opioid needs between benign and malignant colorectal diseases are inconclusive. METHODS: Single institution analysis of prospectively maintained colorectal surgery database. Multiple regression analyses done on perioperative numeric pain scores (NPS) and opioids prescribed at discharge. RESULTS: 641 patients in Benign and 276 patients in the Malignant group. Unadjusted comparison revealed significantly higher NPS for the Benign than the Malignant group preoperative and postoperative day 0 (after surgery), 1, 2, and 3 (all p â€‹≤ â€‹0.001). Opioids prescribed at discharge were significantly higher in the Benign group (60.0% vs 51.1%, p â€‹= â€‹0.018). After regression analysis, there was no longer a significant difference in NPS (B â€‹= â€‹0.703, p â€‹= â€‹0.095) and opioids prescribed between groups [OR â€‹= â€‹0.803 (95%CI 0.586, 1.1), p â€‹= â€‹0.173]. CONCLUSIONS: Pain and opioids prescribed at discharge are not significantly different between benign and malignant diseases in an enhanced recovery pain management pathway that maximizes non-opioid multimodal analgesic strategies.


Subject(s)
Analgesics, Opioid , Colorectal Neoplasms , Pain, Postoperative , Humans , Analgesics, Opioid/therapeutic use , Analgesics, Opioid/administration & dosage , Female , Male , Pain, Postoperative/drug therapy , Middle Aged , Aged , Colorectal Neoplasms/surgery , Pain Measurement , Pain Management/methods , Retrospective Studies , Rectal Diseases/surgery , Colectomy/adverse effects , Colonic Diseases/surgery , Adult
2.
Healthcare (Basel) ; 11(23)2023 Nov 28.
Article in English | MEDLINE | ID: mdl-38063628

ABSTRACT

BACKGROUND: The application of enhanced recovery after surgery principles decreases postoperative complications (POCs), length of stay (LOS), and readmissions. Pharmacoprophylaxis decreases morbidity, but the effect of specific regimens on clinical outcomes is unclear. METHODS AND MATERIALS: Records of 476 randomly selected adult patients who underwent elective colorectal surgeries (ECRS) at 10 US hospitals were abstracted. Primary outcomes were surgical site infection (SSI), venous thromboembolism (VTE), postoperative nausea and vomiting (PONV), pain, and ileus rates. Secondary outcomes included LOS and 7- and 30-day readmission rates. RESULTS: POC rates were SSI (3.4%), VTE (1.5%), PONV (47.9%), pain (58.1%), and ileus (16.1%). Cefazolin 2 g/metronidazole 500 mg and ertapenem 1 g were associated with the shortest LOS; cefotetan 2 g and cefoxitin 2 g with the longest LOS. No SSI occurred with ertapenem and cefotetan. More Caucasians than Blacks received oral antibiotics before intravenous antibiotics without impact. Enoxaparin 40 mg subcutaneously daily was the most common inpatient and discharge VTE prophylaxis. All in-hospital VTEs occurred with unfractionated heparin. Most received rescue rather than around-the-clock antiemetics. Scopolamine patches, spinal opioids, and IV lidocaine continuous infusion were associated with lower PONV. Transversus abdominis plane block with long-acting local anesthetics, celecoxib, non-anesthetic ketamine bolus, ketorolac IV, lidocaine IV, and pregabalin were associated with lower in-hospital pain severity rates. Gabapentinoids and alvimopan were associated with lower ileus rates. Acetaminophen, alvimopan, famotidine, and lidocaine patches were associated with shorter LOS. CONCLUSIONS: Significant differences in pharmacotherapy regimens that may improve primary and secondary outcomes in ECRS were identified. In adult ECRS, cefotetan or ertapenem may be better regimens for preventing in-hospital SSI, while ertapenem or C/M may lead to shorter LOS. The value of OA to prevent SSI was not demonstrated. Inpatient enoxaparin, compared to UFH, may reduce VTE rates with a similar LOS. A minority of patients had a documented PONV risk assessment, and a majority used as-needed rather than around-the-clock strategies. Preoperative scopolamine patches continued postoperatively may lower PONV and PDNV severity and shorter LOS. Alvimopan may reduce ileus and shorten LOS. Anesthesia that includes TAP block, ketorolac IV, and pregabalin use may lead to reduced pain rates. Acetaminophen, alvimopan, famotidine, and lidocaine patches may shorten LOS. Given the challenges of pain management and the incidence of PONV/PDNV found in this study, additional studies should be conducted to determine optimal opioid-free anesthesia and the benefit of newer antiemetics on patient outcomes. Moreover, future research should identify latent pharmacotherapy variables that impact patient outcomes, correlate pertinent laboratory results, and examine the impact of order or care sets used for ECRS at study hospitals.

3.
Surg Endosc ; 37(8): 6097-6106, 2023 08.
Article in English | MEDLINE | ID: mdl-37130983

ABSTRACT

BACKGROUND: Alvimopan is a µ-opioid receptor antagonist associated with shorter time to gastrointestinal recovery in patients having open colorectal surgery. Data demonstrating the benefit of perioperative alvimopan for the minimally invasive surgical approach are inconsistent. The aim of this study is to determine colorectal surgery groups that benefit from perioperative alvimopan. METHODS: This is a retrospective cohort analysis of colorectal surgery patients who had, and patients who did not have, perioperative alvimopan in the Michigan Surgical Quality Collaborative regional risk-adjusted database from 2018 through 2021. Main outcome measures were postoperative length of hospital stay, time to return of bowel function, and postoperative ileus. RESULTS: There were 10,010 patients (30.3% open, 40.5% laparoscopic, 12.7% hand-assist laparoscopic, 43.5% robotic) who met inclusion criteria-4919 received alvimopan in the perioperative period and 5091 did not. When compared to those not receiving alvimopan, unadjusted outcomes showed that the alvimopan group had significantly shorter postoperative length of stay (4.75 days vs 5.5 days, p < 0.001), shorter time to return of bowel function (1.61 days vs 2.01 days, p < 0.001) and less postoperative ileus (5.45% vs 7.94%, p < 0.001). After adjustment, regression models confirmed that alvimopan was associated with an 9.6% reduction in hospital length of stay (p < 0.001), a 14.9% shorter time to return of bowel function (p < 0.001), and a 42.1% reduction in postoperative ileus (p < 0.001). Subgroup analysis showed significant benefit of alvimopan for all three outcomes in patients having the minimally invasive approach. CONCLUSIONS: Alvimopan is associated with shorter hospital length of stay, shorter time to return of bowel function, and decreased postoperative ileus when administered to patients undergoing colorectal surgery. Benefit is not limited to the open approach and includes minimally invasive laparoscopic and robotic colorectal procedures.


Subject(s)
Colorectal Surgery , Digestive System Surgical Procedures , Ileus , Humans , Retrospective Studies , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Postoperative Complications/drug therapy , Ileus/etiology , Ileus/prevention & control , Length of Stay , Gastrointestinal Agents/therapeutic use
4.
J Cardiothorac Vasc Anesth ; 36(12): 4273-4280, 2022 12.
Article in English | MEDLINE | ID: mdl-36216688

ABSTRACT

OBJECTIVE: To determine the safety of performing urgent or emergent cardiac surgery within 5 days of a patient taking a direct oral anticoagulant (DOAC). DESIGN: A multicenter retrospective registry study. SETTING: Thirty-three hospitals in a quality collaborative from 2017 to 2019. PARTICIPANTS: Patients were included if they underwent urgent or emergent coronary artery bypass grafting (CABG). Patients were excluded if they received any anticoagulant or antiplatelet agent besides DOACs, heparin, or aspirin. INTERVENTIONS: Patients were stratified based upon the receipt of a DOAC within 5 days of their surgery. Patient cohorts included DOAC within 2 days, DOAC within 3-to-5 days, and no anticoagulation. Data were unavailable on the specific DOAC agent taken prior to admission. MEASUREMENTS AND MAIN RESULTS: There were 7,201 patients included, with 94 on DOACs. Intraoperative blood transfusion was required in 23.9% of patients on no anticoagulant, 26.2% on a DOAC within 3-to-5 days of surgery (odds ratio [OR] 0.98; 95% CI 0.46-2.11), and 30.3% on a DOAC within 2 days (OR 0.99; 95% CI 0.37-2.67). Five or more intraoperative blood products were required in 4.4% on no anticoagulant, 1.7% on DOAC within 3-to-5 days (OR 0.33; 95% CI 0.04-2.71), and 6.1% on DOAC within 2 days (OR 0.47; 95% CI 0.06-4.05). No difference in mortality was observed among the 3 groups (2.9% v 3.3% v 3.0%; p = 0.67). CONCLUSIONS: For urgent or emergent CABGs, no significant differences in minor bleeding, major bleeding, or mortality were observed in patients taking a DOAC within 5 days of surgery. This study was hypothesis-generating for performing urgent or emergent surgery sooner than 5 days after holding DOACs.


Subject(s)
Anticoagulants , Cardiac Surgical Procedures , Humans , Retrospective Studies , Anticoagulants/adverse effects , Hemorrhage , Platelet Aggregation Inhibitors/therapeutic use , Cardiac Surgical Procedures/adverse effects , Administration, Oral
5.
Surg Endosc ; 36(1): 701-710, 2022 01.
Article in English | MEDLINE | ID: mdl-33569727

ABSTRACT

BACKGROUND: Opioid dependence is a public health crisis and surgery is a risk factor for long-term opioid use. Though minimally invasive surgery (MIS) is associated with less perioperative pain, demonstrating an association with less long-term opioid use would be another reason to justify adoption of minimally invasive techniques. We compared the rates for long-term opioid prescriptions among patients in a large national database who underwent minimally invasive and open colectomy. METHODS: Using the MarketScan Database, we retrospectively analyzed patients undergoing colon resection for benign and malignant diseases between 2013 and 2017. Among opioid-naïve patients who had ≥ 1 opioid prescriptions filled perioperatively (30 days before surgery to 14 days after discharge), propensity score matching was applied for group comparisons [open (OS) versus MIS, and laparoscopic (LS) versus robotic-assisted surgery (RS)]. The primary outcome was long-term opioid use defined as the proportion of patients with ≥ 1 long-term opioid prescriptions filled 90-180 days after discharge. Risks factors for long-term opioid use were assessed using logistic regression. RESULTS: Among the 5413 matched pairs in the MIS versus OS cohorts, MIS significantly reduced long-term opioid use of 'any opioids' (13.3% vs. 20.9%), schedule II/III opioids (11.7% vs. 19.2%), and high-dose opioids (4.3% vs. 7.7%; all p < 0.001). Among the 1195 matched pairs in the RS versus LS cohorts, RS was associated with less high-dose opioids (2.1% vs. 3.8%, p = 0.015) 90-180 days after discharge. Other risk factors for long-term opioid use included younger age, benign indications, tobacco use, mental health conditions, and > 6 Charlson comorbidities. CONCLUSION: Minimally invasive colectomy is associated with a significant reduction in long-term opioid use when compared to OS. Robotic-assisted colectomy was associated with less high-dose opioids compared to LS. Increasing adoption of minimally invasive surgery for colectomy and including RS, where appropriate, may decrease long-term opioid use.


Subject(s)
Laparoscopy , Opioid-Related Disorders , Robotic Surgical Procedures , Analgesics, Opioid/therapeutic use , Colectomy/methods , Humans , Minimally Invasive Surgical Procedures/methods , Opioid-Related Disorders/epidemiology , Opioid-Related Disorders/etiology , Opioid-Related Disorders/prevention & control , Propensity Score , Retrospective Studies
6.
Dis Colon Rectum ; 65(7): e728-e740, 2022 07 01.
Article in English | MEDLINE | ID: mdl-34897213

ABSTRACT

BACKGROUND: Decreasing readmissions is an important quality improvement strategy. Targeted interventions that effectively decrease readmissions have not been fully investigated and standardized. OBJECTIVE: The purpose of this study was to assess the effectiveness of interventions designed to decrease readmissions after colorectal surgery. DESIGN: This was a retrospective comparison of patients before and after the implementation of interventions. SETTING: This study was conducted at a single institution dedicated enhanced recovery pathway colorectal surgery service. PATIENTS: The study group received quality review interventions that were designed to decrease readmissions: preadmission class upgrades, a mobile phone app, a pharmacist-led pain management strategy, and an early postdischarge clinic. The control group was composed of enhanced recovery patients before the interventions. Propensity score weighting was used to adjust patient characteristics and predictors for imbalances. MAIN OUTCOME MEASURE: The primary outcome was 30-day readmissions. Secondary outcomes included emergency department visits. RESULTS: There were 1052 patients in the preintervention group and 668 patients in the postintervention group. After propensity score weighting, the postintervention cohort had a significantly lower readmission rate (9.98% vs 17.82%, p < 0.001) and emergency department visit rate (14.58% vs 23.15%, p < 0.001) than the preintervention group, and surgical site infection type I/II was significantly decreased as a readmission diagnosis (9.46% vs 2.43%, p = 0.043). Median time to readmission was 6 (interquartile 3-11) days in the preintervention group and 8 (3-17) days in the postintervention group (p = 0.21). Ileus, acute kidney injury, and surgical site infection type III were common reasons for readmissions and emergency department visits. LIMITATIONS: A single-institution study may not be generalizable. CONCLUSION: Readmission bundles composed of targeted interventions are associated with a decrease in readmissions and emergency department visits after enhanced recovery colorectal surgery. Bundle composition may be institution dependent. Further study and refinement of bundle components are required as next-step quality metric improvements. See Video Abstract at http://links.lww.com/DCR/B849. ANLISIS EN UNA SOLA INSTITUCIN DE LAS CIRUGAS COLORECTALES CON VAS DE RECUPERACIN DIRIGIDA AUMENTADA QUE REDUCEN LOS REINGRESOS: ANTECEDENTES:La reducción de los reingresos es una importante estrategia de mejora de la calidad. Las intervenciones dirigidas que reducen eficazmente los reingresos no se han investigado ni estandarizado por completo.OBJETIVO:El propósito de este estudio fue evaluar la efectividad de las intervenciones diseñadas para disminuir los reingresos después de la cirugía colorrectal.DISEÑO:Comparación retrospectiva de pacientes antes y después de la implementación de las intervenciones.ESCENARIO:Una sola institución dedicada al Servicio de cirugía colorrectal con vías de recuperación dirigida aumentadaPACIENTES:El grupo de estudio recibió intervenciones de revisión de calidad que fueron diseñadas para disminuir los reingresos: actualizaciones de clases previas a la admisión, una aplicación para teléfono móvil, una estrategia de manejo del dolor dirigida por farmacéuticos y alta temprana de la clínica. El grupo de control estaba compuesto por pacientes con recuperación mejorada antes de las intervenciones. Se utilizó la ponderación del puntaje de propensión para ajustar las características del paciente y los predictores de los desequilibrios.PARÁMETRO DE RESULTADO PRINCIPAL:El resultado primario fueron los reingresos a los 30 días. Los resultados secundarios incluyeron visitas al servicio de urgencias.RESULTADOS:Hubo 1052 pacientes en el grupo de preintervención y 668 pacientes en el grupo de posintervención. Después de la ponderación del puntaje de propensión, la cohorte posterior a la intervención tuvo una tasa de reingreso significativamente menor (9,98% frente a 17,82%, p <0,001) y una tasa de visitas al servicio de urgencias (14,58% frente a 23,15%, p <0,001) que el grupo de preintervención y la infección del sitio quirúrgico tipo I / II se redujo significativamente como diagnóstico de reingreso (9,46% frente a 2,43%, p = 0,043). La mediana de tiempo hasta la readmisión fue de 6 [IQR 3, 11] días en el grupo de preintervención y de 8 [3, 17] días en el grupo de posintervención (p = 0,21). El íleo, la lesión renal aguda y la infección del sitio quirúrgico tipo III fueron motivos frecuentes de reingresos y visitas al servicio de urgencias.LIMITACIONES:El estudio de una sola institución puede no ser generalizable.CONCLUSIÓNES:Los paquetes de readmisión compuestos por intervenciones dirigidas se asocian con una disminución en las readmisiones y las visitas al departamento de emergencias después de una cirugía colorrectal con vías de recuperación dirigida aumentada. La composición del paquete puede depender de la institución. Se requieren más estudios y refinamientos de los componentes del paquete como siguiente paso de mejora de la métrica de calidad. Consulte Video Resumen en http://links.lww.com/DCR/B849. (Traducción-Dr Yolanda Colorado).


Subject(s)
Colorectal Surgery , Aftercare , Humans , Patient Discharge , Patient Readmission , Retrospective Studies , Surgical Wound Infection
7.
Dis Colon Rectum ; 64(6): 735-743, 2021 06 01.
Article in English | MEDLINE | ID: mdl-33955408

ABSTRACT

BACKGROUND: The current opioid crisis has motivated surgeons to critically evaluate ways to balance postoperative pain while decreasing opioid use and thereby reducing opioids available for community diversion. The longest incision for robotic colorectal surgery is the specimen extraction site incision. Intracorporeal techniques allow specimen extraction to be at any location. OBJECTIVE: This study was designed to determine whether the Pfannenstiel location is associated with less pain and opioid use than other abdominal wall specimen extraction sites. DESIGN: This was a retrospective cohort study. SETTINGS: The study was conducted with a prospectively maintained colorectal surgery database (July 2018 through October 2019). PATIENTS: Patients with enhanced recovery robotic colorectal resections with specimen extraction were included. MAIN OUTCOME MEASURES: Propensity score weighting was used to derive adjusted rates for numeric pain scores, inpatient opioid use, opioids prescribed at discharge, opioid refills after discharge, and other related outcomes. For comparing outcomes between groups, p values were calculated using weighted χ2, Fisher exact, and t tests. RESULTS: There were 137 cases (70.9%) with Pfannenstiel extraction site incisions and 56 (29.0%) at other locations (7 midline, 49 off-midline). There was no significant difference in transversus abdominis plane blocks and epidural analgesia use between groups. Numeric pain scores, overall benefit of analgesia scores, inpatient postoperative opioid use, opioids prescribed at discharge and taken after discharge, and opioid refills were not significantly different between groups. Nonopioid pain analgesics (acetaminophen, nonsteroidal anti-inflammatory drugs, and gabapentin) prescribed at discharge were significantly less in the Pfannenstiel group (90.19% vs 98.45%; p = 0.006). Postoperative complications and readmissions were not different between groups. LIMITATIONS: This study was conducted at a single institution. CONCLUSIONS: The Pfannenstiel incision as the specimen extraction site choice in minimally invasive surgery is associated with similar postoperative pain and opioid use as extraction sites in other locations for patients having robotic colorectal resections. Specimen extraction sites may be chosen based on patient factors other than pain and opioid use. See Video Abstract at http://links.lww.com/DCR/B495. DOLOR POSTOPERATORIO DESPUS DE VAS DE RECUPERACIN MEJORADA EN CIRUGA ROBTICA DE COLON Y RECTO IMPORTA EL LUGAR DE EXTRACCIN DE LA MUESTRA: ANTECEDENTES:La actual crisis de opioides ha motivado a los cirujanos a evaluar críticamente, formas para equilibrar el dolor postoperatorio, disminuyendo el uso de opioides y por lo tanto, disminuyendo opioides disponibles para el desvío comunitario. La incisión más amplia en cirugía colorrectal robótica, es la incisión del sitio de extracción de la muestra. Las técnicas intracorpóreas permiten que la extracción de la muestra se realice en cualquier sitio.OBJETIVO:El estudio fue diseñado para determinar si la ubicación del Pfannenstiel está asociada con menos dolor y uso de opioides, a otros sitios de extracción de la muestra en la pared abdominal.DISEÑO:Estudio de cohorte retrospectivo.AJUSTES:Estudio de base de datos de cirugía colorrectal mantenida prospectivamente (7/2018 a 10/2019).PACIENTES:Se incluyeron resecciones robóticas colorrectales con recuperación mejorada y extracción de muestras.PRINCIPALES MEDIDAS DE RESULTADO:Se utilizó la ponderación del puntaje de propensión para derivar las tasas ajustadas para los puntajes numéricos de dolor, uso de opioides en pacientes hospitalizados, opioides recetados al alta, recarga de opioides después del alta y otros resultados relacionados. Para comparar los resultados entre los grupos, los valores p se calcularon utilizando chi-cuadrado ponderado, exacto de Fisher y pruebas t.RESULTADOS:Hubo 137 (70,9%) casos con incisiones en el sitio de extracción de Pfannenstiel y 56 (29,0%) en otras localizaciones (7 en la línea media, 49 fuera de la línea media). No hubo diferencias significativas en los bloqueos del plano transverso del abdomen y el uso de analgesia epidural entre los grupos. Las puntuaciones numéricas de dolor, puntuaciones de beneficio general de la analgesia, uso postoperatorio de opioides en pacientes hospitalizados, opioides recetados al alta y tomados después del alta, y las recargas de opioides, no fueron significativamente diferentes entre los grupos. Los analgésicos no opioides (acetaminofén, antiinflamatorios no esteroideos, gabapentina) prescritos al alta, fueron significativamente menores en el grupo de Pfannenstiel (90,19% frente a 98,45%, p = 0,006). Las complicaciones postoperatorias y los reingresos, no fueron diferentes entre los grupos.LIMITACIONES:Una sola institución.CONCLUSIÓN:La incisión de Pfannenstiel como sitio de extracción de la muestra en cirugía mínimamente invasiva, se asocia con dolor postoperatorio y uso de opioides similar, a otros sitios de extracción en pacientes sometidos a resecciones robóticas colorrectales. Sitios de extracción de la muestra, pueden elegirse en función de factores del paciente distintos al dolor y uso de opioides. Consulte Video Resumen en http://links.lww.com/DCR/B495.).


Subject(s)
Analgesics, Opioid/therapeutic use , Colorectal Surgery/instrumentation , Enhanced Recovery After Surgery/standards , Pain, Postoperative/drug therapy , Robotic Surgical Procedures/adverse effects , Aged , Analgesics, Opioid/supply & distribution , Colorectal Surgery/statistics & numerical data , Data Management , Female , Humans , Male , Middle Aged , Opioid-Related Disorders/epidemiology , Opioid-Related Disorders/prevention & control , Pain, Postoperative/epidemiology , Pain, Postoperative/prevention & control , Patient Discharge/standards , Patient Discharge/statistics & numerical data , Patient Readmission/statistics & numerical data , Postoperative Complications/epidemiology , Postoperative Period , Propensity Score , Retrospective Studies , Specimen Handling/methods , Surgical Wound/pathology
8.
Healthcare (Basel) ; 9(3)2021 Mar 16.
Article in English | MEDLINE | ID: mdl-33809571

ABSTRACT

Surgical procedures are key drivers of pain development and opioid utilization globally. Various organizations have generated guidance on postoperative pain management, enhanced recovery strategies, multimodal analgesic and anesthetic techniques, and postoperative opioid prescribing. Still, comprehensive integration of these recommendations into standard practice at the institutional level remains elusive, and persistent postoperative pain and opioid use pose significant societal burdens. The multitude of guidance publications, many different healthcare providers involved in executing them, evolution of surgical technique, and complexities of perioperative care transitions all represent challenges to process improvement. This review seeks to summarize and integrate key recommendations into a "roadmap" for institutional adoption of perioperative analgesic and opioid optimization strategies. We present a brief review of applicable statistics and definitions as impetus for prioritizing both analgesia and opioid exposure in surgical quality improvement. We then review recommended modalities at each phase of perioperative care. We showcase the value of interprofessional collaboration in implementing and sustaining perioperative performance measures related to pain management and analgesic exposure, including those from the patient perspective. Surgery centers across the globe should adopt an integrated, collaborative approach to the twin goals of optimal pain management and opioid stewardship across the care continuum.

9.
Clin Infect Dis ; 72(8): 1404-1412, 2021 04 26.
Article in English | MEDLINE | ID: mdl-32155264

ABSTRACT

BACKGROUND: ß-Lactam antibiotics are first-line therapy for perioperative prophylaxis; however, patient-reported allergies often lead to increased prescribing of alternative antibiotics that may increase the incidence of surgical site infections. The R-group side chain of the ß-lactam ring is responsible for allergic cross-reactivity and experts recommend the use of ß-lactams that are structurally dissimilar. METHODS: An internally developed, antibiotic side-chain-based cross-reactivity chart was developed and implemented alongside enhanced allergy assessment processes. This single-center, quasi-experimental study analyzed antibiotic prescribing in all adult patients with a documented ß-lactam allergy undergoing an inpatient surgical procedure between quartile (Q) 1 (2012)-Q3 (2014) (historical group) and Q3 (2016)-Q3 (2018) (intervention group). Propensity-weighted scoring analyses compared categorical and continuous outcomes. Interrupted time-series analysis further analyzed key outcomes. RESULTS: A total of 1119 and 1089 patients were included in the historical and intervention cohorts, respectively. There was a significant difference in patients receiving a ß-lactam alternative antibiotic between cohorts (84.9% vs 15.1%; P < .001). There was a decrease in 30-day readmissions in the intervention cohort (7.9% vs 6.3%; P = .035); however, there was no difference in the incidence of SSIs in patients readmitted (14.8% vs 13%; P = .765). No significant differences were observed in allergic reactions (0.5% vs 0.3%; P = .323), surgical site infections, in-hospital and 30-day mortality, healthcare facility-onset Clostridiodes difficile infection, acute kidney injury, or hospital costs. CONCLUSIONS: Implementation of an antibiotic cross-reactivity chart combined with enhanced allergy assessment processes significantly improved the prescribing of ß-lactam antibiotics for surgical prophylaxis.


Subject(s)
Anti-Infective Agents , Drug Hypersensitivity , Adult , Anti-Bacterial Agents/adverse effects , Antibiotic Prophylaxis , Humans , Surgical Wound Infection/drug therapy , Surgical Wound Infection/prevention & control , beta-Lactams/adverse effects
10.
Am J Health Syst Pharm ; 76(16): 1219-1225, 2019 Aug 01.
Article in English | MEDLINE | ID: mdl-31369118

ABSTRACT

PURPOSE: Results of a study incorporating real-world results into a predictive model to assess the cost-effectiveness of procalcitonin (PCT)-guided antibiotic use in intensive care unit patients with sepsis are reported. METHODS: A single-center, retrospective cross-sectional study was conducted to determine whether reductions in antibiotic therapy duration and other care improvements resulting from PCT testing and use of an associated treatment pathway offset the costs of PCT testing. Selected base-case cost outcomes in adults with sepsis admitted to a medical intensive care unit (MICU) were assessed in preintervention and postintervention cohorts using a decision analytic model. Cost-minimization and cost-utility analyses were performed from the hospital perspective with a 1-year time horizon. Secondary and univariate sensitivity analyses tested a variety of clinically relevant scenarios and the robustness of the model. RESULTS: Base-case modeling predicted that use of a PCT-guided treatment algorithm would results in hospital cost savings of $45 per patient and result in a gain of 0.0001 quality-adjusted life-year. After exclusion of patients in the postintervention cohort for PCT test ordering outside of institutional guidelines, the mean inpatient antibiotic therapy duration was significantly reduced in the postintervention group relative to the preintervention group (6.2 days versus 4.9 days, p = 0.04) after adjustment for patient sex and age, Charlson Comorbidity Index score, study period, vasopressor use, and ventilator use. Total annual hospital cost savings of $4,840 were predicted. CONCLUSION: Real-world implementation of PCT-guided antibiotic use may have improved patients' quality of life while decreasing hospital costs in MICU patients with undifferentiated sepsis.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Drug Monitoring/economics , Procalcitonin/blood , Sepsis/drug therapy , Aged , Bacterial Infections/blood , Bacterial Infections/mortality , Biomarkers/blood , Cost Savings , Cost-Benefit Analysis , Critical Pathways/economics , Critical Pathways/organization & administration , Cross-Sectional Studies , Drug Costs , Drug Monitoring/methods , Female , Health Plan Implementation/economics , Hospital Costs , Hospital Mortality , Humans , Intensive Care Units/economics , Intensive Care Units/organization & administration , Male , Middle Aged , Models, Economic , Program Evaluation , Quality-Adjusted Life Years , Retrospective Studies , Sepsis/blood , Sepsis/mortality
11.
Dis Colon Rectum ; 61(10): 1196-1204, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30192328

ABSTRACT

BACKGROUND: Multimodal pain management is an integral part of enhanced recovery pathways. The most effective pain management strategies have not been determined. OBJECTIVE: The purpose of this study was to compare liposomal bupivacaine transversus abdominis plane block with epidural analgesia in patients undergoing colorectal surgery. DESIGN: This is a single-institution, open-label randomized (1:1) trial. SETTING: This study compared liposomal bupivacaine transversus abdominis plane block with epidural analgesia in patients undergoing elective open and minimally invasive colorectal surgery in an enhanced recovery pathway. PATIENTS: Two hundred were enrolled. Following randomization, allocation, and follow-up, there were 92 patients with transversus abdominis plane block and 87 patients with epidural analgesia available for analysis. INTERVENTIONS: The interventions comprised liposomal bupivacaine transversus abdominis plane block versus epidural analgesia. MAIN OUTCOME MEASURES: The primary outcomes measured were numeric pain scores and the overall benefit of analgesia scores. RESULTS: There were no significant differences in the Numeric Pain Scale and Overall Benefit of Analgesia Score between groups. Time trend analysis revealed that patients with transversus abdominis plane block had higher numeric pain scores on the day of surgery, but that the relationship was reversed later in the postoperative period. Opioid use was significantly less in the transversus abdominis plane block group (206.84 mg vs 98.29 mg, p < 0.001). There were no significant differences in time to GI recovery, hospital length of stay, and postoperative complications. Cost was considerably more for the epidural analgesia group. LIMITATIONS: This study was conducted at a single institution. CONCLUSIONS: This randomized trial shows that perioperative pain management with liposomal bupivacaine transversus abdominis plane block is as effective as epidural analgesia and is associated with less opioid use and less cost. These data and the more favorable risk profile suggest that liposomal bupivacaine transversus abdominis plane block is a viable multimodal perioperative pain management option for this patient population in an established enhanced recovery pathway. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov (NCT02591407). See Video Abstract at http://links.lww.com/DCR/A737.


Subject(s)
Abdominal Muscles/drug effects , Analgesia, Epidural/methods , Bupivacaine/pharmacology , Colon/surgery , Colorectal Surgery/standards , Nerve Block/methods , Pain, Postoperative/drug therapy , Abdominal Muscles/innervation , Abdominal Muscles/physiopathology , Adult , Analgesia, Epidural/economics , Analgesia, Epidural/statistics & numerical data , Analgesics, Opioid/administration & dosage , Analgesics, Opioid/therapeutic use , Anesthetics, Local/administration & dosage , Anesthetics, Local/pharmacology , Bupivacaine/administration & dosage , Digestive System Surgical Procedures/adverse effects , Female , Humans , Male , Middle Aged , Outcome Assessment, Health Care , Pain Management/methods , Pain Management/standards , Pain Measurement/methods , Perioperative Care/standards , Postoperative Period
SELECTION OF CITATIONS
SEARCH DETAIL
...